Q4 FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Mar 10, 2026
Q32 Bio Inc. (QTTB) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$4.5 million. As of Sep 30, 2026 it held $289.6 million in cash and investments and $5.1 million in total debt.
Revenue
$0
Net income
$-8.92M
-20.7% vs year-ago quarter
Operating cash flow
$-4.42M
-4.4% vs year-ago quarter
Free cash flow
$-4.47M
-5.7% vs year-ago quarter
EPS
$-0.26
+56.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
29.92M
+143.2% vs year-ago quarter
Net cash
$284.46M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- QTTB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1661998
- Former names
- Q32 Bio Inc. (until Nov 4, 2026); Homology Medicines, Inc. (until Mar 22, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$10.7M | -$9.1M | -$7.7M | $45.9M | -$7.6M |
| Net income | -$8.9M | -$8.9M | -$7.6M | $57.7M | -$7.4M |
| Diluted EPS | -$0.26 | -$0.44 | -$0.54 | $2.21 | -$0.60 |
| Operating cash flow | -$4.4M | -$3.1M | -$6.3M | -$6.2M | -$4.2M |
| Free cash flow | -$4.5M | — | — | -$6.2M | -$4.2M |
| Total assets | $297.2M | $115.9M | $63.7M | $61.8M | $57.8M |
| Total liabilities | $9.5M | $10.0M | $17.4M | $19.8M | $76.2M |
| Stockholders' equity | $287.7M | $105.9M | $46.3M | $42.0M | -$18.4M |
| Cash and investments | $289.6M | $106.3M | $50.8M | $48.3M | $49.0M |
| Total debt | $5.1M | $5.3M | $5.5M | $5.6M | $5.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
All 588 Q32 Bio Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.